Summit Therapeutics Inc

NASDAQ:SMMT  
1.03
+0.01 (+0.98%)
Earnings Announcements

Summit Therapeutics Reports Results For First Quarter Ended March 31, 2022

Published: 05/11/2022 22:40 GMT
Summit Therapeutics Inc (SMMT) - Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022.
Summit Therapeutics Inc - Qtrly Loss per Share $0.22.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.27

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.